You are here:

Home
NICE Guidance
Conditions and diseases
Blood and immune system conditions
Blood and bone marrow cancers

Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

Technology appraisal guidance
Reference number: TA218
Published: 23 March 2011

Guidance
Tools and resources
Information for the public
History

Response to scrutiny letter

Celgene response to initial scrutiny letter
Celgene appeal letter amended

This page was last updated: 27 May 2010